Table 2.

Patient characteristics and survival data of PDXs in CGM097 survival study.

Patient characteristics						Survival Data
PDX	TP53 genotype	Sex (m/f)	Age (years)	WHO	Phase of Treatment	Vehicle (days)	CGM097 (days)
86438	WT	f	48	MLLr	Persistent, post-induction	10	83
29894	WT	f	5	NOS	Untreated	19	111
88779	WT	f	5	NOS	Untreated	13	75
87017	WT	f	8	NOS	Relapsed	8	36
47294	WT	m	50	NOS	Relapsed, post-allogeneic transplant	20	80
55918	WT		1	MLLr	Untreated	55	156
79275	WT	f	12	NOS	Untreated	24	73
91898	WT	f	83	NOS	Untreated	21	53
82812	WT	f	5	NOS	Untreated	44	108
13601	WT	f	59	Ph+	Relapsed, post-allogeneic transplant	28	65
62876	WT	m	36	Ph+	Relapsed	11	25
93213	WT		0.3	MLLr	Untreated	32	67
44464	WT	m	3	hypodiploid	Untreated	41	77
70486	WT	m	15	NOS	Relapsed	70	110
97113	WT	f	54	MLLr	Untreated	37	56
73571	WT	m	26	NOS	Untreated	37	56
66654	WT	m	30	MLLr	Untreated	88	132
60588	WT	f	12	NOS	Relapsed	28	39
74952	WT	f	44	Ph+	Untreated	35	47
34953	WT	f	20	B/myeloid	Untreated	86	86
88178	N239D	m	15	MLLr	Untreated	24	24
56198	Y220C	m	71	hypodiploid	Untreated	90	76
56336	D61fs	m	13	hypodiploid	Untreated	20	16
97613	C275G	f	2	hypodiploid	Untreated	27	27
97626	WT	m	6	NOS	Untreated	>120	>120
44038	WT	m	59	NOS	Untreated	>120	>120

WHO = World Health Organization classification. MLLr = MLL-rearranged, NOS= Not Otherwise Specified, Ph⁺= Philadelphia-positive, hypodiploid= <44 chromosomes, B/myeloid= mixed phenotype